Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis

PURPOSE: REACH investigated second-line ramucirumab therapy for advanced hepatocellular carcinoma. RESULTS: Median overall survival was 8.2 months for ramucirumab and 6.9 months for placebo (HR, 0.835; 95% CI, 0.634–1.100; p = 0.2046) for East Asians, and 10.1 months for ramucirumab and 8.0 months f...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Kudo, Masatoshi, Yang, Ling, Abada, Paolo B., Cheng, Rebecca, Orlando, Mauro, Zhu, Andrew X., Okusaka, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342754/
https://www.ncbi.nlm.nih.gov/pubmed/27776351
http://dx.doi.org/10.18632/oncotarget.12780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342754/
https://www.ncbi.nlm.nih.gov/pubmed/27776351
http://dx.doi.org/10.18632/oncotarget.12780

Ejemplares similares